Galimedix Therapeutics, Inc.
0 followers
Galimedix Therapeutics is a Phase 2 neuropharmaceutical company developing novel first-in-class drugs with ground-breaking potential to slow or stop the progression of neurodegeneration and to improve function in glaucoma and dry AMD – leading causes of blindness – and also in Alzheimer’s disease.
Org chart
Andrew Pearlman
Collapse
Christopher Parsons
Chief Pharmacologist & VP Of Non-clinical Development
Yaniv Barkana
Chief Medical Officer, Galimedix Therapeutics
Dr. Luciana Summo
Vice President R&d Operations
Phyllis Bellin
Chief Financial Officer
